We serve Chemical Name:(4-propanoylphenyl)boronic acid CAS:186498-36-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(4-propanoylphenyl)boronic acid
CAS.NO:186498-36-2
Synonyms:4-propanoylphenylboronic acid
Molecular Formula:C9H11BO3
Molecular Weight:177.99300
HS Code:2931900090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:362.2ºC at 760mmHg
Density:1.16g/cm3
Index of Refraction:1.529
PSA:57.53000
Exact Mass:178.08000
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-propanoylphenylboronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-propanoylphenylboronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-propanoylphenylboronic acid Use and application,4-propanoylphenylboronic acid technical grade,usp/ep/jp grade.
Related News: UQUIFA is a manufacturer of APIs and intermediates for the pharmaceutical industry globally. The company has 3 manufacturing sites (2 in Spain and 1 in Mexico) with strict adherence to all regulatory norms. Butanenitrile, 3-bromo-2-methyl- manufacturers He further explained that getting a new drug to commercial manufacturing is also complex and costly due to the very stringent drug manufacturing regulatory mechanism. 2,4-Pteridinediamine, 7-(4-methoxyphenyl)- suppliers UQUIFA is a manufacturer of APIs and intermediates for the pharmaceutical industry globally. The company has 3 manufacturing sites (2 in Spain and 1 in Mexico) with strict adherence to all regulatory norms. (S)-2-((S)-2-((S)-1-acetylpyrrolidine-2-carboxamido)-3-methylbutanamido)-N1-propyl-N5-tritylpentanediamide vendor & factory He further explained that getting a new drug to commercial manufacturing is also complex and costly due to the very stringent drug manufacturing regulatory mechanism. ,The plant will complement Recipharm’s existing sites in France, Germany and Italy and will be focused on securing approvals from regulators in Europe and the U.S.
